0.1638
price down icon1.80%   -0.003
after-market Handel nachbörslich: .17 0.0062 +3.79%
loading
Schlusskurs vom Vortag:
$0.1668
Offen:
$0.17
24-Stunden-Volumen:
1.22M
Relative Volume:
0.25
Marktkapitalisierung:
$13.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.88M
KGV:
-0.2184
EPS:
-0.75
Netto-Cashflow:
$-25.20M
1W Leistung:
-4.77%
1M Leistung:
+8.41%
6M Leistung:
-50.91%
1J Leistung:
-83.59%
1-Tages-Spanne:
Value
$0.1581
$0.17
1-Wochen-Bereich:
Value
$0.1581
$0.176
52-Wochen-Spanne:
Value
$0.133
$1.74

In 8 Bio Inc Stock (INAB) Company Profile

Name
Firmenname
In 8 Bio Inc
Name
Telefon
(646) 600-6438
Name
Adresse
EMPIRE STATE BUILDING, NEW YORK
Name
Mitarbeiter
18
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
INAB's Discussions on Twitter

Vergleichen Sie INAB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INAB
In 8 Bio Inc
0.1638 13.98M 0 -31.88M -25.20M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.03 129.44B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.52 61.42B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
615.11 38.44B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
269.81 33.29B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
241.75 26.95B 3.81B -644.79M -669.77M -6.24

In 8 Bio Inc Stock (INAB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-03-18 Eingeleitet Laidlaw Buy
2022-08-30 Eingeleitet H.C. Wainwright Buy

In 8 Bio Inc Aktie (INAB) Neueste Nachrichten

pulisher
May 05, 2025

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th - TradingView

May 05, 2025
pulisher
May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025
pulisher
May 01, 2025

Nuvation Bio CFO to Share Latest Oncology Strategy at Exclusive Citizens Conference Next Week - Stock Titan

May 01, 2025
pulisher
May 01, 2025

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and - GlobeNewswire

May 01, 2025
pulisher
Apr 29, 2025

Annovis Bio Appoints Hui Liu as Director of Biostatistics - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting - Yahoo Finance

Apr 29, 2025
pulisher
Apr 27, 2025

Cerity Partners LLC Makes New Investment in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Apr 27, 2025
pulisher
Apr 20, 2025

TELA Bio to Announce Q1 2025 Earnings on May 8 - MSN

Apr 20, 2025
pulisher
Apr 18, 2025

TELA Bio to Announce First Quarter 2025 Financial Results - The Manila Times

Apr 18, 2025
pulisher
Apr 17, 2025

Tevogen Bio Signs Agreement with CD 8 Technology - TipRanks

Apr 17, 2025
pulisher
Apr 16, 2025

Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1? - Insider Monkey

Apr 16, 2025
pulisher
Apr 16, 2025

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

Vyant Bio (OTCMKTS:VYNT) Trading 7.8% Higher – Time to Buy? - Defense World

Apr 15, 2025
pulisher
Apr 09, 2025

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire

Apr 09, 2025
pulisher
Apr 09, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 8, 2025 - BioSpace

Apr 09, 2025
pulisher
Apr 08, 2025

South Korean firms ABL Bio, Yuhan advance bispecific antibodies in cancer treatmentCHOSUNBIZ - Chosunbiz

Apr 08, 2025
pulisher
Apr 07, 2025

High Growth Tech Stocks Including ABL Bio To Watch - Yahoo

Apr 07, 2025
pulisher
Apr 07, 2025

ABL Bio lands $2.8 billion license-out deal with GSK - KED Global

Apr 07, 2025
pulisher
Apr 01, 2025

GRI Bio Reports Encouraging Interim 2-Week Safety Results - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

SEC Form 424B5 filed by Instil Bio Inc. - Quantisnow

Mar 31, 2025
pulisher
Mar 28, 2025

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Healthcare Spotlight: Climb Bio Takes Center Stage at Major Needham Conference - Stock Titan

Mar 27, 2025
pulisher
Mar 25, 2025

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - Quantisnow

Mar 25, 2025
pulisher
Mar 21, 2025

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Quantisnow

Mar 21, 2025
pulisher
Mar 21, 2025

Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 18, 2025

Kronos Bio Inc (KRON) Q4 2024 Earnings: EPS Misses at -$0.43, Re - GuruFocus.com

Mar 18, 2025
pulisher
Mar 17, 2025

GRI Bio Reports Full Year 2024 Financial Results and - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Short Interest in bluebird bio, Inc. (NASDAQ:BLUE) Drops By 26.8% - Defense World

Mar 17, 2025
pulisher
Mar 15, 2025

10 Most Oversold Penny Stocks to Buy According to Analysts - Insider Monkey

Mar 15, 2025
pulisher
Mar 15, 2025

Analysts Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $8.33 - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Gossamer Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 14, 2025
pulisher
Mar 12, 2025

Palisade Bio Announces Two Abstracts Selected to be - GlobeNewswire

Mar 12, 2025
pulisher
Mar 11, 2025

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders - Joplin Globe

Mar 11, 2025
pulisher
Mar 11, 2025

GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 11, 2025
pulisher
Mar 10, 2025

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire

Mar 10, 2025
pulisher
Mar 09, 2025

Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts - Yahoo Finance

Mar 09, 2025
pulisher
Mar 07, 2025

Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView

Mar 07, 2025
pulisher
Mar 06, 2025

Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

One-step Cre-loxP organism creation by TAx9Communications Biology - Nature

Mar 06, 2025
pulisher
Mar 04, 2025

Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire

Mar 04, 2025
pulisher
Mar 03, 2025

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - Yahoo Finance

Mar 03, 2025
pulisher
Mar 03, 2025

Canadian North Resources Inc. Expands Metallurgical Programs Applying Low-carbon Footprint Bioleaching Technology on Ferguson Lake Ni-Cu-Co PGE project - Yahoo Canada Finance

Mar 03, 2025

Finanzdaten der In 8 Bio Inc-Aktie (INAB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.42
price down icon 5.24%
$67.87
price down icon 6.49%
$32.11
price down icon 2.70%
$24.20
price down icon 13.63%
$94.74
price down icon 6.29%
biotechnology ONC
$241.75
price down icon 4.88%
Kapitalisierung:     |  Volumen (24h):